Key takeaway
In a crossover trial of 33 people with traumatic brain injury and sleep problems, 2 mg prolonged-release melatonin lowered Pittsburgh Sleep Quality Index scores versus placebo (7.68 vs 9.47; difference -1.79; 95% CI -2.70 to -0.88), meaning better sleep quality, but it did not change sleep onset latency. The trial was small, lasted 4 weeks per treatment, and ran at two Melbourne hospitals.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Sleep disturbance is common after traumatic brain injury (TBI) and has few proven treatments. The authors tested whether melatonin supplements improve sleep in outpatients with mild to severe TBI who reported sleep problems since their injury.
Who and how
Randomised, double-blind, placebo-controlled, two-period crossover trial. Outpatients were recruited from Epworth and Austin Hospitals in Melbourne, Australia. 33 people with mild to severe TBI took part (mean age 37 years, SD 11; 67% men). Each took prolonged-release melatonin (2 mg; Circadin) and placebo capsules for 4 weeks each, in counterbalanced order, separated by a 48-hour washout. Treatment was taken nightly 2 hours before bedtime. Serious adverse events and side-effects were monitored. Outcomes included the global Pittsburgh Sleep Quality Index, sleep onset latency, actigraphy sleep efficiency and several questionnaires.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Melatonin lowered global Pittsburgh Sleep Quality Index scores versus placebo, indicating better sleep quality (7.68 vs 9.47; difference -1.79; 95% CI -2.70 to -0.88; p ≤ 0.0001).
- 2Melatonin had no effect on sleep onset latency (1.37 vs 1.42 log units; difference -0.05; 95% CI -0.14 to 0.03; p = 0.23).
- 3Among secondary outcomes, melatonin increased actigraphy sleep efficiency, and vitality and mental health on the SF-36 (p ≤ 0.05 for each). It decreased anxiety on the Hospital Anxiety Depression Scale and fatigue on the Fatigue Severity Scale (p ≤ 0.05 for both).
- 4Daytime sleepiness on the Epworth Sleepiness Scale did not change significantly (p = 0.15).
- 5No serious adverse events were reported.
Limits & uncertainty
- 133 participants from two hospitals in one city is a small sample, and the abstract reports no sample size calculation.
- 2Each treatment lasted only 4 weeks, so longer-term benefit and safety are unknown.
- 3The primary measure, the Pittsburgh Sleep Quality Index, is self-reported, and the many secondary outcomes were tested without a stated correction for multiple comparisons.
- 4The abstract does not say whether the sleep improvement is large enough to matter to patients, and this reading is based on the abstract only.
What to take from it
In this small trial, a bedtime dose of melatonin was associated with better self-rated sleep quality and some better daytime measures in people with TBI-related sleep problems, but it did not help them fall asleep faster. It does not show that melatonin will work for you or is right at any dose. Talk to your clinician before starting any sleep supplement after a head injury.
Reading your own data
Sleep efficiency from actigraphy is something many wrist trackers estimate. If you try a sleep aid with your clinician, compare weeks of sleep duration and efficiency on the same device before and after, and note how rested you feel. Consumer sleep numbers are estimates and single nights vary a lot.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
The study aimed to determine the efficacy of melatonin supplementation for sleep disturbances in patients with traumatic brain injury (TBI).
Methods
This is a randomised double-blind placebo-controlled two-period two-treatment (melatonin and placebo) crossover study. Outpatients were recruited from Epworth and Austin Hospitals Melbourne, Australia. They had mild to severe TBI (n = 33) reporting sleep disturbances post-injury (mean age 37 years, standard deviation 11 years; 67% men). They were given prolonged-release melatonin formulation (2 mg; Circadin®) and placebo capsules for 4 weeks each in a counterbalanced fashion separated by a 48-hour washout period. Treatment was taken nightly 2 hours before bedtime. Serious adverse events and side-effects were monitored.
Results
Melatonin supplementation significantly reduced global Pittsburgh Sleep Quality Index scores relative to placebo, indicating improved sleep quality [melatonin 7.68 vs. placebo 9.47, original score units; difference -1.79; 95% confidence interval (CI), -2.70 to -0.88; p ≤ 0.0001]. Melatonin had no effect on sleep onset latency (melatonin 1.37 vs. placebo 1.42, log units; difference -0.05; 95% CI, -0.14 to 0.03; p = 0.23). With respect to the secondary outcomes, melatonin supplementation increased sleep efficiency on actigraphy, and vitality and mental health on the SF-36 v1 questionnaire (p ≤ 0.05 for each). Melatonin decreased anxiety on the Hospital Anxiety Depression Scale and fatigue on the Fatigue Severity Scale (p ≤ 0.05 for both), but had no significant effect on daytime sleepiness on the Epworth Sleepiness Scale (p = 0.15). No serious adverse events were reported.
Conclusions
Melatonin supplementation over a 4-week period is effective and safe in improving subjective sleep quality as well as some aspects of objective sleep quality in patients with TBI.
Trial registration
Identifier: 12611000734965; Prospectively registered on 13 July 2011.
Sources & attribution
Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial.
Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL.
BMC medicine · 2018-01-19
DOI: 10.1186/s12916-017-0995-1 ↗PubMed · 29347988 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Exercise improved sleep-quality scores in adults 45 and older with sleep disorders
Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.
Journal of Exercise Science & Fitness
Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults
Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.
Sleep
Sleep extension cut daily energy intake by about 270 kcal in adults with overweight
In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.
JAMA Internal Medicine
Six hours or less of sleep at 50 and 60 linked to higher dementia risk
In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.
Nature Communications

